Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexofenadine for PPI-refractory GERD
NCT03425097Phase 2Terminated
- Sponsor
- Stanford University
- Start
- Feb 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fexofenadine in gastroesophageal reflux disease (GERD), sponsored by Stanford University. Started Feb 2018; status: terminated.
02
Drugs
fexofenadine
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03425097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425097.